Zymogenetics, Inc.

Osteoscreen, Inc.

Other

Becton Dickinson and Company Limited

Microprobe, Inc.

Epoch Pharmaceuticals, Inc.

University of Texas System

Charles R Petrie

Nand Baindur

Mark W Orme

Gregory R Mundy

Kirk G Robbins

Maria Kontoyianni

Patricia A McKernan

John C Tabone

Emma E Moore

Rich B Meyer, Jr

Scott M Harris

Richard Allen Houghten

John M Ostresh

Clemencia Pinilla

Jean-Philippe Meyer

Jeffrey Van Ness

Michael W Reed

Virender M Labroo

Laurence H Hurley

Sean Michael Kerwin

Theresa Martinez

Nicolaas M Vermeulen

Stephanie Beigel

Gerald D Hurst

Steven Stroop

Igor V Kutyavin

Alexander A Gall

Robert R West

James R Piggott

Howard B Gamper

Shirley R Gasper

A David Adams

Lennie Chen

Mark V Craig

Colin Lellis

Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or &ldquo;linker&rdquo; defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 &angst;, are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.

Compositions and methods for treating bone deficit conditions

Compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. Included among the calcitonin mimetics of the present invention are substituted piperazines. The calcitonin mimetics of the present invention are also useful in libraries and in assays for the determination of calcitonin receptor activity.

Calcitonin mimetics

Dialkyl urea compounds are described which act as calcitonin mimetics. These compounds are useful in the treatment of diseases which are associated with bone resorption. The calcitonin mimetics of the present invention are also useful in assays for the determination of calcitonin receptor activity.

Dialkyl ureas as calcitonin mimetics

Compounds containing two aromatic systems covalently linked through a linker containing one or more atoms, or 'linker' defined as including a covalent bond per se so as to space the aromatic systems at a distance 1.5-15 .ANG., are effective in treating conditions associated with bone deficits. The compounds can be administered to vertebrate subjects alone or in combination with additional agents that promote bone growth or that inhibit bone resorption. They can be screened for activity prior to administration by assessing their ability to effect the transcription of a reporter gene coupled to a promoter associated with a bone morphogenetic protein and/or their ability to stimulate calvarial growth in model animal systems.

Growing community of inventors

Woodinville, WA, United States of America

Charles R Petrie